CD8A and neoplasm: Given that EGFR-mediated signalling has been established to upregulate PD-L1 expression on tumour cells [32,33,34,35,36], it had originally been hypothesized that the treatment landscape for such cancers could be revolutionized by CD8 T-cell enhancing immunotherapies like PD-L1 inhibitors [11].